

Nigeria

Population 2017

191 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	120 (70–180)	63 (36–96)
Mortality (HIV+TB only)	35 (21–52)	18 (11–27)
Incidence (includes HIV+TB)	418 (273–594)	219 (143–311)
Incidence (HIV+TB only)	58 (37–85)	30 (19–44)
Incidence (MDR/RR-TB)**	24 (14–36)	12 (7.3–19)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	27 (11–43)	123 (50–196)	150 (72–228)
Males	30 (12–48)	238 (97–379)	268 (128–408)
Total	57 (32–82)	361 (203–520)	418 (273–594)

TB case notifications, 2017	
Total cases notified	104 904
Total new and relapse	102 387
- % tested with rapid diagnostics at time of diagnosis	41%
- % with known HIV status	95%
- % pulmonary	96%
- % bacteriologically confirmed among pulmonary	78%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	24% (17–38)
TB patients facing catastrophic total costs, 2017	71% (68–73)
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.38 (0.2–0.59)

TB/HIV care in new and relapse TB patients, 2017		
	Number	(%)
Patients with known HIV-status who are HIV-positive	13 516	14%
- on antiretroviral therapy	11 438	85%

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			5 400 (4 200–6 500)
Estimated % of TB cases with MDR/RR-TB	4.3% (3.2–5.5)	25% (19–31)	
% notified tested for rifampicin resistance	41%	61%	43 829
MDR/RR-TB cases tested for resistance to second-line drugs			691
Laboratory-confirmed cases		MDR/RR-TB: 2 286, XDR-TB: 14	
Patients started on treatment ****		MDR/RR-TB: 1 786, XDR-TB: 10	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2016	86%	97 240
Previously treated cases, excluding relapse, registered in 2016	83%	3 193
HIV-positive TB cases registered in 2016	77%	14 794
MDR/RR-TB cases started on second-line treatment in 2015	78%	656
XDR-TB cases started on second-line treatment in 2015		0

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	39%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	20% (18–21)

TB financing, 2018	
National TB budget (US\$ millions)	409
Funding source: 8% domestic, 16% international, 76% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically